Beta-Myrcene

Phase 1Small molecule

JJohns Hopkins University

Beta-Myrcene is one of 8 small molecule programs targeting Cannabis Use. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cannabis UseNot yet recruiting

Cannabis UsePhase 1

Not yet recruiting

Competition

Competitive Landscape

7 competitors in Cannabis Use

#DrugCompanyPhaseTrials

Mounjaro

Eli Lilly

Approved

1 2

Epidiolex

Jazz Pharmaceuticals

Phase 2

3 3

Intuniv

PPromius Pharma, LLC

Phase 2

1 4

Bscbd Cannabidiol

UUniversity of Colorado, Boulder

Phase 2

1 5

Fscbd Cannabidiol

UUniversity of Colorado, Boulder

Phase 2

1 6

Broad Spectrum Cannabidiol

UUniversity of Colorado, Denver

Phase 2

1 7

Tetrahydrocannabinol

HHadassah Medical Organization

Preclinical

1 8

Beta-Myrcene

JJohns Hopkins University

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Not yet recruiting

Cannabis Use

NCT05432284

Clinical

Trials by Indication[1]

Cannabis Use1 trial

Behavioral Pharmacology of THC and Beta-Myrcene

Not yet recruiting·JJohns Hopkins University·Phase 1·NCT05432284·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Beta-Myrcene. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Beta-Myrcene compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Beta-Myrcene. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johns Hopkins University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: JJohns Hopkins University

Beta-Myrcene

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Cannabis Use1 trial

References

Drug Info

Quick Facts

Related News